The Janssen Pharmaceutical Companies of Johnson & Johnson announced last week (November 23) the submission of a type 2 extension of indication application to the European Medicines Agency (EMA).
Dr. Susan Wood is CEO and president of VIDA Diagnostics. She has over 25 years of experience championing clinical intelligence solutions into routine clinical use.
The excipients, equipment, and API companies have joined forces on Inhalation Together, an initiative aimed at advancing dry-powder inhalation solutions.
The artificial intelligence-driven drug discovery company has dosed its first healthy volunteer in a trial for a candidate to treat idiopathic pulmonary fibrosis.
The firm is investigating viability of voriconazole inhalation powder, intended to treat and prevent invasive pulmonary aspergillosis in asthma patients.
The respiratory care specialist shares perspective on issues faced by respiratory studies, and how to overcome such obstacles to get therapies to market.
The agency’s effort to fight the deadly disease now includes taps the pharma company’s testing tools to help speed up diagnosis and grow treatment access.
The project will use the artificial intelligence specialist’s cell-centered models and deconvolutions to gain insights for each individual asthma endotype.
Artificial intelligence software company Thirona has released PRAGMA-AI, technology that automates and accelerates CT scans in cystic fibrosis analysis.
The immunotherapy-focused firm reports enrollment stands at 55% for its ongoing study exploring viability of Ampion as an inhalable COVID-19 treatment.
UK researchers have started developing a 'lung in a test tube',
that could aid research into respiratory diseases such as asthma
and allergy and reduce the need for animal testing.
Merck & Co has signed a $32m deal to evaluate MicroDose
Technologies' dry powder inhalation technology in the delivery of
some of its respiratory product lines.
While the market performance of Exubera may have fallen short of
expectations, Pfizer's inhaled insulin has opened the door for a
wider variety of macromolecules to take the pulmonary delivery
route.
US researchers have identified a specific pathway that causes
inflammation in lung tissue, a discovery that could help in the
design of more targeted drug treatments for patients with various
lung diseases, including cystic fibrosis,...
A new inhaled formulation of insulin that could do away with the
need for diabetics to inject themselves before meals has been filed
for approval in Europe by Aventis and Pfizer and the dossier
accepted by the European Medicines Evaluation...